Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
Abstract
Background Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. Methods In two prospective, double-blind, multicentre, phase 3 studies (UNCOVER-2 and UNCOVER-3), eligible patients were aged 18 years or older, had a confirmed diagnosis of chronic plaque psoriasis at least 6 months before baseline (randomisation), 10% or greater body-surface area involvement at both screening and baseline visits, at least a moderate clinical severity as measured by a static physician global assessment (sPGA) score of 3 or more, and a psoriasis area and severity index (PASI) score of 12. Participants were randomly assigned (1:2:2:2) by computer-generated random sequence with an interactive voice response system to receive subcutaneous placebo, etanercept (50 mg twice weekly), or one injection of 80 mg ixekizumab every 2 weeks, or every 4 weeks after a 160 mg starting dose. Blinding was maintained with a double-dummy design. Coprimary efficacy endpoints were proportions of patients achieving sPGA score 0 or 1 and 75% or greater improvement in PASI at week 12. Analysis was by intention to treat. These trials are registered with ClinicalTrials.gov, numbers NCT01597245 and NCT01646177. Findings Between May 30, 2012, and Dec 30, 2013, 1224 patients in UNCOVER-2 were randomly assigned to receive subcutaneous placebo (n=168), etanercept (n=358), or ixekizumab every 2 weeks (n=351) or every 4 weeks (n=347); between Aug 11, 2012, and Feb 27, 2014, 1346 patients in UNCOVER-3 were randomly assigned to receive placebo (n=193), etanercept (n=382), ixekizumab every 2 weeks (n=385), or ixekizumab every 4 weeks (n=386). At week 12, both primary endpoints were met in both studies. For UNCOVER-2 and UNCOVER-3 respectively, in the ixekizumab every 2 weeks group, PASI 75 was achieved by 315 (response rate 89·7%; [effect size 87·4% (97·5% CI 82·9-91·8) vs placebo; 48·1% (41·2-55·0) vs etanercept]) and 336 (87·3%; [80·0% (74·4-85·7) vs placebo; 33·9% (27·0-40·7) vs etanercept]) patients; in the ixekizumab every 4 weeks group, by 269 (77·5%; [75·1% (69·5-80·8) vs placebo; 35·9% (28·2-43·6) vs etanercept]) and 325 (84·2%; [76·9% (71·0-82·8) vs placebo; 30·8% (23·7-37·9) vs etanercept]) patients; in the placebo group, by four (2·4%) and 14 (7·3%) patients; and in the etanercept group by 149 (41·6%) and 204 (53·4%) patients (all p<0·0001 vs placebo or etanercept). In the ixekizumab every 2 weeks group, sPGA 0/1 was achieved by 292 (response rate 83·2%; [effect size 80·8% (97·5% CI 75·6-86·0) vs placebo; 47·2% (39·9-54·4) vs etanercept]) and 310 (80·5%; [73·8% (67·7-79·9) vs placebo; 38·9% (31·7-46·1) vs etanercept]) patients; in the ixekizumab every 4 weeks group by 253 (72·9%; [70·5% (64·6-76·5) vs placebo; 36·9% (29·1-44·7) vs etanercept]) and 291 (75·4%; [68·7% (62·3-75·0) vs placebo; 33·8% (26·3-41·3) vs etanercept]) patients; in the placebo group by four (2·4%) and 13 (6·7%) patients; and in the etanercept group by 129 (36·0%) and 159 (41·6%) patients (all p<0·0001 vs placebo or etanercept). In combined studies, serious adverse events were reported in 14 (1·9%) of 734 patients given ixekizumab every 2 weeks, 14 (1·9%) of 729 given ixekizumab every 4 weeks, seven (1·9%) of 360 given placebo, and 14 (1·9%) of 739 given etanercept; no deaths were noted. Interpretation Both ixekizumab dose regimens had greater efficacy than placebo and etanercept over 12 weeks in two independent studies. These studies show that selectively neutralising interleukin 17A with a high affinity antibody potentially gives patients with psoriasis a new and effective biological therapy option. Funding Eli Lilly and Co.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Expression of IL-10 and co-inhibitory molecules marks a general anti-inflammatory module that can be induced by IL-27 in any T cell subset.
“Conversely, expression of IL-10 and co-inhibitory molecules marks a general anti-inflammatory module that can be induced by IL-27 in any T cell subset [105, 178–180].”
From TH17 cell heterogeneity and its role in tissue inflammation (2023) · cites this paper as [105]
Cites
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,788 · see citing works
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · see citing works
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N. M., Guzzo, C. A., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,870 · see citing works
Self-citationLowes, M. A., Suárez‐Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,710 · see citing works
Psoriasis causes as much disability as other major medical diseases
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70112-x · Cited by 1,489 · see citing works
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414 · see citing works
Papp, K. A., Langley, R. G. B., Lebwohl, M., Krueger, G. G., Szapary, P. O., Yeilding, N. M., Guzzo, C. A., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,358 · see citing works
Self-citationEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., POWERS, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R. J., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,173 · see citing works
Reich, K., Nestle, F. O., Papp, K. A., Ortonne, J. P., Evans, R., Guzzo, C. A., Li, S., Dooley, L. T., & Griffiths, C. E. M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045 · see citing works
Self-citationStrange, A., Spencer, C. C. A., Band, G., Bellenguez, C., Freeman, C., Pirinen, M., Rautanen, A., Su, Z., Donnelly, P., Capon, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.694 · Cited by 1,042 · see citing works
Self-citationIdentification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
Collaborative Association Study of Psoriasis (CASP), Tsoi, L. C., Genetic Analysis of Psoriasis Consortium, Psoriasis Association Genetics Extension, Wellcome Trust Case Control Consortium 2, Spain, S. L., Knight, J., Ellinghaus, E., Stuart, P. E., Capon, F., et al. (2012) · Nature Genetics · doi:10.1038/ng.2467 · Cited by 1,024 · see citing works
Self-citationAnti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C. L., Matheson, R. T., Zachariae, C. O. C., Cameron, G. S., LI, L. C., Edson‐Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 933 · see citing works
Self-citationBrodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Papp, K. A., Leonardi, C. L., Menter, A., Ortonne, J. P., Krueger, J. G., Kricorian, G., Aras, G. A., Li, J., Russell, C. B., Thompson, E. H. Z., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109017 · Cited by 932 · see citing works
Self-citationAdalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K. B., Kimball, A. B., Leonardi, C. L., Langley, R. G. B., Strober, B. E., Kaul, M., Gu, Y., Okun, M. M., et al. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 886 · see citing works
Self-citationHueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860 · see citing works
Hongbo, Y., Thomas, C. L., Harrison, M., Salek, S., & Finlay, A. Y. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23621.x · Cited by 857 · see citing works
Guidelines of care for the management of psoriasis and psoriatic arthritis
Gottlieb, A. B., Korman, N. J., Gordon, K. B., Feldman, S. R., Lebwohl, M., Koo, J. Y. M., Voorhees, A. S. V., Elmets, C. A., Leonardi, C. L., Beutner, K. R., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.02.040 · Cited by 766 · see citing works
Self-citationEuropean S3‐Guidelines on the systemic treatment of psoriasis vulgaris
Pathirana, D., Ormerod, A., Saïag, P., Smith, C. H., Spuls, P. I., Nast, A., Barker, J. N., Bos, J. D., Burmester, G. R., Chimenti, S., et al. (2009) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03389.x · Cited by 700 · see citing works
Self-citationPapp, K. A., Tyring, S. K., Lahfa, M., Prinz, J. C., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R. J., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 691 · see citing works
Self-citationGuidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Leonardi, C. L., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.11.055 · Cited by 458 · see citing works
Self-citationKimball, A. B., Gladman, D. D., Gelfand, J. M., Gordon, K. B., Horn, E. J., Korman, N. J., Korver, G., Krueger, G. G., Strober, B. E., & Lebwohl, M. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.01.006 · Cited by 431 · see citing works
Self-citationIL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis
Krueger, J. G., Fretzin, S., Suárez‐Fariñas, M., Haslett, P. A. J., Phipps, K. M., Cameron, G. S., McColm, J., Katcherian, A., Cueto, I., White, T. R., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.024 · Cited by 383 · see citing works
Self-citationPapp, K. A., Langley, R. G. B., Sigurgeirsson, B., Abe, M., Baker, D. R., Konno, P., Hämmerle, S. P., Thurston, H. J., Papavassilis, C., & Richards, H. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12110 · Cited by 360 · see citing works
Self-citationPsoriasisPreprint
Meglio, P. D., Villanova, F., & Nestle, F. O. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015354 · Cited by 315 · see citing works
Rich, P., Sigurgeirsson, B., Thaçi, D., Ortonne, J. ‐., Paul, C. F., Schopf, R. E., Morita, A., Roseau, K., Harfst, E., Guettner, A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12112 · Cited by 244 · see citing works
Self-citationKimball, A. B., Papp, K. A., Wasfi, Y. S., Chan, D., Bissonnette, R., Sofen, H. L., Yeilding, N. M., Li, S., Szapary, P. O., Gordon, K. B., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12046 · Cited by 215 · see citing works
Self-citationSampogna, F., Tabolli, S., & ABENI, D. D. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1273 · Cited by 198 · see citing works
PASI 90 response: the new standard in therapeutic efficacy for psoriasis
Puig, L. (2014) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12817 · Cited by 191 · see citing works
Rich, P., Sigurgeirsson, B., Thaçi, D., Ortonne, J. ‐., Paul, C. F., Schopf, R. E., Morita, A., Roseau, K., Harfst, E., Guettner, A., et al. (2012) · British Journal of Dermatology · doi:10.1111/bjd.12070 · Cited by 189 · see citing works
Self-citationHueber, W., Patel, D. D., Dryja, T. P., Wright, A., Bruin, G. J. M., Antoni, C., Gold, M. H., Durez, P., Tak, P. P., Go, J. J., et al. (2010) · Cited by 151 · see citing works
Papp, K. A., Reid, C., Foley, P. A., Sinclair, R. D., Salinger, D. H., Williams, G., Dong, H., Krueger, J. G., Russell, C. B., & Martin, D. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.163 · Cited by 143 · see citing works
Self-citationSafety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
Papp, K. A., Leonardi, C. L., Menter, A., Thompson, E. H. Z., Milmont, C. E., Kricorian, G., Nirula, A., & Klekotka, P. A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.08.039 · Cited by 116 · see citing works
Self-citationGordon, K. B., Leonardi, C. L., Lebwohl, M., Blauvelt, A., Cameron, G. S., Braun, D. K., Erickson, J., & Heffernan, M. P. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.07.048 · Cited by 107 · see citing works
Self-citationReich, K., & Mrowietz, U. (2007) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2007.06343.x · Cited by 93 · see citing works
Self-citationTakeshita, J., Duffin, K. C., Shin, D. B., Krueger, G. G., Robertson, A. D., Troxel, A. B., Voorhees, A. S. V., & Gelfand, J. M. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.001 · Cited by 80 · see citing works
Viswanathan, H. N., Chau, D., Milmont, C. E., et al. (2014) · Journal of Dermatological Treatment · doi:10.3109/09546634.2014.943687 · Cited by 80 · see citing works
Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments
Mazzotta, A., Esposito, M., Costanzo, A., et al. (2009) · American Journal of Clinical Dermatology · doi:10.2165/11310770-000000000-00000 · Cited by 76 · see citing works
Xie, L., Lewis-Beck, Baser, et al. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s39887 · Cited by 75 · see citing works
Torii, H., Sato, N., Yoshinari, T., et al. (2011) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2011.01459.x · Cited by 71 · see citing works
Nemoto, O., Nagashima, H., Sayama, K., et al. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.05.007 · Cited by 30 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans.
Smith, S. H., Jayawickreme, C., Rickard, D. J., Nicodeme, E., Bui, T., Simmons, C., Coquery, C. M., Neil, J., Pryor, W. M., Mayhew, D., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.004 · Cited by 387 · see citing works
TH17 cell heterogeneity and its role in tissue inflammation
Schnell, A., Littman, D. R., & Kuchroo, V. K. (2023) · Nature Immunology · doi:10.1038/s41590-022-01387-9 · Cited by 286 · see citing works
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192 · see citing works
Skin changes in the obese patient
Hirt, P. A., Castillo, D. E., Yosipovitch, G., & Keri, J. E. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.12.070 · Cited by 182 · see citing works
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91 · see citing works
Psoriasis and Depression: The Role of Inflammation
González-Parra, S., & Daudén, E. (2019) · Actas Dermo-Sifiliográficas (English Edition) · doi:10.1016/j.adengl.2018.05.035 · Cited by 70 · see citing works
- Authors
- Griffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., Ball, S., Braun, D. K., Osuntokun, O. O., Heffernan, M. P., Nickoloff, B. J., & Papp, K.
- Affiliations
- Manchester Academic Health Science Centre (GB)
- Dermatologikum Hamburg (DE)
- Icahn School of Medicine at Mount Sinai (US)
- Université Toulouse III - Paul Sabatier (FR)
- The University of Texas Southwestern Medical Center (US)
- Eli Lilly (United States) (US)
- Probity Medical Research (CA)
- Corresponding author
- Griffiths, Christopher E M
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 386
- Issue
- 9993
- Pages
- 541-551
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2171889601
- Cited by
- 834
- References
- 40
- Citations by year
- 2026: 27 · 2025: 34 · 2024: 53 · 2023: 56 · 2022: 59 · 2021: 60 · 2020: 96 · 2019: 97 · 2018: 107 · 2017: 120 · 2016: 94 · 2015: 29 · 2013: 1
- FWCI
- 57.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Eli Lilly and Company
- National Institute for Health and Care Research
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- etanercept, psoriasis, IL-17A, IL-17A inhibition, monoclonal antibodies, plaque psoriasis, treatment efficacy, treatment safety, adverse events, PASI improvement, double-dummy design, dosing interval, biologic therapy
- MeSH terms
- Etanercept, Adult, Anti-Inflammatory Agents, Non-Steroidal, Chronic Disease, Double-Blind Method, Drug Administration Schedule, Female, Humans, Immunoglobulin G, Male, Middle Aged, Prospective Studies, Psoriasis, Treatment Outcome, Receptors, Tumor Necrosis Factor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
